Neurocrine Biosciences, Inc. (NBIX) Given a $85.00 Price Target by Oppenheimer Holdings, Inc. Analysts
NBIX has been the subject of a number of other research reports. Robert W. Baird reiterated a buy rating and set a $84.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Piper Jaffray Companies reiterated a buy rating and set a $76.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Jefferies Group LLC reiterated a buy rating and set a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Deutsche Bank AG reiterated a buy rating and set a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, BMO Capital Markets reiterated an outperform rating and set a $84.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 5th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $78.88.
Shares of Neurocrine Biosciences (NASDAQ NBIX) traded down $0.47 during midday trading on Tuesday, hitting $74.17. The stock had a trading volume of 832,400 shares, compared to its average volume of 1,127,112. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the business earned ($0.43) EPS. sell-side analysts forecast that Neurocrine Biosciences will post -1.74 EPS for the current fiscal year.
In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 6,925 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares in the company, valued at $3,412,013.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Haig P. Bozigian sold 26,250 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now owns 144,601 shares of the company’s stock, valued at $8,676,060. The disclosure for this sale can be found here. Insiders have sold 140,810 shares of company stock valued at $9,035,398 over the last 90 days. Company insiders own 4.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its position in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares in the last quarter. Comerica Bank acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $210,000. Trexquant Investment LP acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $246,000. World Asset Management Inc acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $246,000. Finally, Stifel Financial Corp acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $246,000.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.